SPRB Spruce Biosciences
- 0.770
- +0.016+2.09%
Spruce Biosciences News
Spruce Biosciences to Participate in May Investor Conferences
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
Presentation to highlight baseline characteristics of Spruce's CAHptain program evaluating tildacerfont in pediatric congenital adrenal hyperplasia (CAH)The company is also highlighting baseline chara
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
Presentation to highlight baseline characteristics of Spruce's CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease
Spruce Biosciences(SPRB.US) 10% Shareholder Sells US$350.95K in Common Stocks
$Spruce Biosciences(SPRB.US)$ 10% Shareholder Novo Holdings A/S sold 465.02K shares of Common Stocks on Mar 21, 2024 at an average price of $0.7547 for a total value of $350.95K.Source: Announcement W
Revenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)
Spruce Biosciences(SPRB.US) 10% Shareholder Sells US$1.36 Million in Common Stocks
$Spruce Biosciences(SPRB.US)$ 10% Shareholder Novo Holdings A/S sold 1.79 million shares of Common Stocks on Mar 18, 19, 20, 2024 at an average price of $0.757 for a total value of $1.36 million.Sourc
Spruce Biosciences(SPRB.US) 10% Shareholder Sells US$1.7 Million in Common Stocks
$Spruce Biosciences(SPRB.US)$ 10% Shareholder Novo Holdings A/S sold 1.91 million shares of Common Stocks on Mar 14, 2024 at an average price of $0.8884 for a total value of $1.7 million.Source: Annou
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Spruce Biosciences (SPRB)
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages...
Spruce Biosciences, Inc. (NASDAQ:SPRB) Just Reported Earnings, And Analysts Cut Their Target Price
Health Check: How Prudently Does Spruce Biosciences (NASDAQ:SPRB) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Spruce Biosciences' Hormone Treatment Stumbles In Trials, Prompts Stock Freefall
Spruce Biosciences faces setbacks as tildacerfont trials fail primary endpoints, raising concerns about drug efficacy and compliance. Analysts downgrade ratings and adjust price targets amid uncertainty.
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Top Midday Decliners
Spruce Biosciences (SPRB) slumped 81% after top-line results from its CAHmelia-203 study of tildacerfont in adult classic congenital adrenal hyperplasia with severe hyperandrogenemia failed to meet it
Spruce Biosciences Touches 52-Week Low After Unfavorable Genetic Disease Study Results
By Josh Beckerman Spruce Biosciences touched a 52-week low Thursday following Wednesday's news of unfavorable clinical trial results and job cuts and multiple analyst downgrades Thursday. The stock
WIMI, FWBI and BMR Among Mid-day Movers
Crude Oil Moves Higher; Dollar General Posts Upbeat Earnings
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.30% to 38,926.22 while the NASDAQ fell 0.44% to 16,107.04. The
US Stocks Higher; Producer Prices Rise 0.6% In February
U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.11% to 39,084.58 while the NASDAQ rose 0.30% to 16,226.13. The S&P
Why Is Rare Endocrine Disorder-Focused Spruce Biosciences Stock Plummeting On Thursday?
Wednesday, Spruce Biosciences Inc (NASDAQ:SPRB) released topline results from its CAHmelia-203 Phase 2b study of tildacerfont in adult classic congenital adrenal hyperplasia (CAH) and its CAHptain-205
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
Health care stocks were mixed premarket Thursday with the Health Care Select Sector SPDR Fund (XLV) up 0.27% while the iShares Biotechnology ETF (IBB) was down 1%. Mirum Pharmaceuticals (MIRM) was up
Analysis
Price Target
No Data
